News & Events

actogenix_press_06

STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS

STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX’s technology for targeted delivery of allergen-based treatments

Antony, ...

actogenix_news_01-670x270

Oral therapeutic proteins: a game changer for inflammatory and autoimmune disorders

Nature | Biopharmadealmakers| November 2014

Oral therapeutic proteins: a game changer for inflammatory and autoimmune disorders

This new class of ...

actogenix_page_02

ActoGeniX Announces Positive Results From a Phase 1 Study of AG014

 

ActoGeniX Announces Positive Results From a Phase 1 Study of AG014; Oral Capsule Administration of an Anti-TNF-Alpha Antibody for...

Bacteria as a vehicle for drug delivery

WIPO | MAGAZINE August 2014

ActoGeniX, a small Belgian biotech company, is breaking new ground in developing a new class ...

jefLogo

Jefferies 2014 Global Healthcare Conference

November 19-20, 2014
Waldorf Hilton, London

http://tinyurl.com/mxaundo

 ...

BEU14_logo_150x75

BIO-Europe 2014 – Presentation

November 3-5, 2014
Portalhaus Messe Frankfurt, Germany

http://tinyurl.com/24hv85e

 ...

logo

Flemish Biotech and Life Sciences week (Japan)

October 14 – 20, 2014
Japan

http://tinyurl.com/q5dk7zh

 ...

actogenix_press_06

STALLERGENES and ActoGeniX to develop together an innovative new class of oral treatments for allergy

STALLERGENES to develop and commercialize novel oral allergy drugs based on ActoGeniX’s proprietary local mucosal delivery technology ActoGeniX eligible for...
actogenix_press_06

ActoGeniX closes EUR 10.7 million financing round

Ghent, Belgium – April 18th, 2013

ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Series B equity financing round, ...

flandersbio

Knowledge for Growth – Presentation

May 30, 2013
ICC Ghent

http://knowledgeforgrowth.be/...